🔗 Share this article

While America continues making sweeping revisions to its vaccine schedules, a particular individual appears in a surprising turn: Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about coronavirus vaccines throughout the pandemic and has zeroed in on alleged deaths following COVID-19 immunization in her short tenure at the FDA.

Planned Shifts to Pediatric Immunization Schedule

Public health authorities had intended to announce radical changes to the childhood vaccination calendar recently, bringing the US with the Danish immunization schedule, sources say – a substantial departure that would put the US at odds with many the global community with insufficient data for public health gain. The planned update has been delayed until the coming year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the office this calendar year.

Consolidating Power at the FDA

The acting appointment may indicate a closer partnership between the drug and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it points to a renewed priority upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has often pushed for ending certain pediatric vaccine recommendations in the US so as to align more in line with Denmark, a society with universal health coverage and a number of inhabitants approximately the population of the state of Wisconsin.

To date statements, she has kept her attention on vaccination policy – typically the domain of Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Expertise

The appointee has no obvious background in medication creation, approval processes or leadership, which has been customary for former directors of the biologics center. She has served at the FDA as a senior adviser to the commissioner and CBER since March.

“It seems she lacks to have the necessary background” for running the CDER, said Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in leading a major agency. She lacks background in industry regulation.”

Past heads of the center would “understand laws and regulations and the underlying principles of medication creation”, commented Janet Woodcock. “Frankly, she lacks the kind of background that previous people who led CBER have had.”

The drug center has an enormous range of responsibilities at the FDA, Woodcock pointed out.

“The public just pays attention on the new drug program, but the generic drug division clears a multitude of off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and more, and every single one have to be supervised,” Dr. Woodcock explained. “The area you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a substantial leadership aspect to the position, which manages over 5,000 personnel. “It is a enormous management job, if you execute it properly,” the former official said.

Response and Disputed Policies

In response to questions about Dr. Høeg's qualifications and whether this assignment signifies increased cooperation among FDA leaders on immunizations, a spokesperson stated that the “concerns are based on flawed presumptions”.

“This background aligns with the functions of her position,” the spokesperson stated, pointing to the time Høeg spent guiding the FDA commissioner on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg takes over the commissioner’s recently launched priority voucher program, a disputed expedited therapy clearance system that apparently worried her preceding directors. “By what process are these drugs being chosen for this fast-track system? Who is making the decisions?” Howard questioned. “There’s a lot of confidentiality going on at the regulatory body right now.”

Broadly speaking, he remarked, “the agency appears to be shifting towards laxer oversight of most medications, except for immunizations.”

Documented Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if problematic, history, some experts have noted. She published a research paper using non-validated volunteer-provided data to estimate the frequency of heart inflammation following COVID-19 vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the current government included altering guidelines for recently developed shots and ending “unnecessary” vaccines, she remarked following the vote on a online show. At the agency, Høeg has allegedly proposed excluding adolescent males from obtaining Covid vaccines.

“She is an complete ideologue who starts off with her preconceived notions and works backwards to fit the data in a extremely deceptive, dishonest way,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|